Showing results (1971-1980 of 3,796) with videos related to

Sort By:
Pageof 380
Oncoimmunology|September 14, 2020
Complement inhibitor factor H expressed by breast cancer cells differentiates CD14+ human monocytes into immunosuppressive macrophagesKarolina I Smolag, Christine M Mueni, Karin Leandersson, et al.
Oncoimmunology|March 12, 2020
A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumabWei Nie, Jie Qian, Mi-Die Xu, et al.
Oncoimmunology|March 12, 2020
Lactate dehydrogenase: a marker of diminished antitumor immunitySandra Van Wilpe, Rutger Koornstra, Martijn Den Brok, et al.
Oncoimmunology|March 3, 2020
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneityShumei Kato, Ryosuke Okamura, Yuichi Kumaki, et al.
Oncoimmunology|March 3, 2020
Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune systemSjoerd Klarenbeek, Chris W Doornebal, Sjors M Kas, et al.
Oncoimmunology|October 28, 2020
Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patientsPamela Baldin, Marc Van den Eynde, Bernhard Mlecnik, et al.
Oncoimmunology|July 12, 2021
Prognostic value of the PrPC-ILK-IDO1 axis in the mesenchymal colorectal cancer subtypeAlexandre Ghazi, Delphine Le Corre, Camilla Pilati, et al.
Oncoimmunology|July 12, 2021
TIGIT+ TIM-3+ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinomaLihua Yu, Xiaoli Liu, Xinhui Wang, et al.
Oncoimmunology|June 14, 2021
Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cellsDandan Fan, Qi Yue, Jian Chen, et al.
Oncoimmunology|June 14, 2021
Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patientsS T Paijens, A Vledder, D Loiero, et al.
Pageof 380